Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC)

被引：0
|
作者：
Kim, Y. [1 ]
Goto, K. [1 ]
Yoh, K. [1 ]
Niho, S. [1 ]
Ohmatsu, H. [1 ]
Kubota, K. [1 ]
Saijo, N. [1 ]
Nishiwaki, Y. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18023
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Second-line chemotherapy and its evaluation in small cell lung cancer
    Huisman, C
    Postmus, PE
    Giaccone, G
    Smit, EF
    CANCER TREATMENT REVIEWS, 1999, 25 (04) : 199 - 206
  • [22] Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL) with CPT-11: A retrospective analysis
    Lopez Jimenez, A.
    Esquerdo, G.
    Barrajon, E.
    Del Rio Pazos, L.
    Cervera, J.
    Diaz, N.
    Angeles Oyonarte, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] PROGNOSTIC FACTORS IN PATIENTS WITH SMALL CELL LUNG-CANCER (SCLC)
    EARL, HM
    SOUHAMI, RL
    ASH, CM
    SPIRO, SG
    GEDDES, D
    HARPER, PG
    TOBIAS, JS
    BRITISH JOURNAL OF CANCER, 1987, 56 (06) : 897 - 897
  • [24] Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer
    Wakuda, Kazushige
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (09) : 822 - 826
  • [25] Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients
    Cesano, A
    Lane, SR
    Poulin, R
    Ross, G
    Fields, SZ
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (06) : 1233 - 1238
  • [26] Effect of Topotecan as Second-Line Chemotherapy for Small Cell Lung Cancer Patients with Interstitial Lung Disease
    Suzuki, H.
    Hirashima, T.
    Kobayashi, M.
    Sasada, S.
    Okamoto, N.
    Uehara, N.
    Matsuura, Y.
    Tamiya, M.
    Morishita, N.
    Higashiguchi, M.
    Tsumori, T.
    Kawase, I.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (06) : 367 - 370
  • [27] COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
    Su, W.
    Rengarajan, B.
    Profant, D.
    Mayo, K.
    Groff, M.
    Tremblay, G.
    Ganti, A. K.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [28] Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer
    Georgoulias, VA
    LUNG CANCER, 2002, 38 : S61 - S66
  • [29] Second-line chemotherapy with cyclophosphamide, doxorubicin and vincristine (CAV) in patients with small cell lung cancer (SCLC) initially treated with platinum and etoposide.
    Moreau, S
    Labrune, S
    Gozy, M
    Giraud, V
    Le Guillou, F
    Blivet, S
    Chinet, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [30] Second-line chemotherapy for non-small-cell lung cancer.
    Fossella F.V.
    Current Oncology Reports, 2000, 2 (1) : 96 - 101
12345